Legal developments in trademark registration and protection in Kazakhstan in the pharmaceuticals sector

Following amendments to Kazakhstan's intellectual property framework aligned with EAEU trade commitments, foreign pharmaceutical companies operating in or entering the Kazakhstani market now face a materially revised set of requirements for trademark registration, protection, and enforcement. The changes affect brand owners across the full commercial lifecycle – from initial Kazpatent filing through to market authorisation linkage, parallel import controls, and customs border measures. For multinational pharmaceutical companies managing regional portfolios, and for the foreign counsel instructing local teams on Kazakhstan IP law, understanding these developments is both urgent and practically consequential.

Kazakhstan's trademark registration system is administered by Kazpatent, the national patent office, operating under the intellectual property framework of the Civil Code and dedicated IP legislation. For foreign pharmaceutical companies, trademark registration in Kazakhstan has historically required a separate national application – distinct from any EAEU-level filing – because Kazakhstan, while a founding member of the Eurasian Economic Union, maintains its own national IP register alongside the EAEU's regional trademark mechanism.

Recent years have seen a series of incremental reforms that, taken together, represent a meaningful shift in the operating environment for pharmaceutical trademark holders. First, Kazakhstan has progressively aligned its examination standards with EAEU norms, meaning that absolute grounds for refusal – including descriptiveness of international non-proprietary names (INNs), generic pharmaceutical terms, and colour marks commonly used in pharmaceutical packaging – are now assessed with greater consistency against EAEU-level guidance. In practice, this has led Kazpatent examiners to apply stricter scrutiny to marks that are descriptive of therapeutic class or mechanism, a development that directly affects brand owners filing new pharmaceutical trademarks or defending existing registrations on relative grounds.

Second, the linkage between trademark registration and the pharmaceutical market authorisation process has grown tighter. Kazpatent and the healthcare regulatory authority have incrementally moved towards procedural coordination, with the result that unregistered marks may attract greater scrutiny during the market authorisation process for pharmaceuticals. The practical effect is that trademark registration in Kazakhstan is no longer purely a risk-mitigation step that can be deferred until commercial launch – it has become an integral part of the regulatory pathway for pharmaceutical products.

Third, enforcement mechanisms against counterfeit pharmaceutical goods have been strengthened through amendments to customs border measures and to administrative liability provisions. Kazakhstan Customs now has broader authority to detain suspected infringing goods – including pharmaceutical products – at the border on the basis of ex officio action, not solely on the application of a trademark holder. For foreign pharmaceutical companies, this represents both an opportunity (enhanced border protection at no direct cost of application) and a risk management consideration (the need to maintain an up-to-date customs recordal with accurate product descriptions and authorised importer details).

"The convergence of EAEU examination norms with Kazpatent national procedure has created a dual-track registration environment that many regional pharmaceutical portfolios were not built to navigate." – Aigerim Serikbayeva, Contributing Regional Analyst — Kazakhstan · EAEU Trade, Customs & Market Entry

The reforms affect foreign pharmaceutical companies across three principal business models present in the Kazakhstani market.

For multinational pharmaceutical companies that hold patents and trademarks and supply the Kazakhstani market through local distributors or representative offices, the primary implication is the need to audit existing trademark portfolios for Kazakhstan-specific coverage. A trademark registered in the European Union, Russia, or under the EAEU regional mechanism does not automatically confer rights enforceable before Kazakhstani courts or at the Kazpatent level. Portfolio gaps – particularly for second-generation product names, combination products, and device-associated marks – now carry real commercial risk given the tighter market authorisation linkage described above.

For generic pharmaceutical manufacturers entering Kazakhstan or expanding their distribution footprint, the stricter examination of INN-adjacent marks and descriptive terms introduces early-stage filing risk. Applications for marks that derive strength from a broadly descriptive root – a common practice in the generics sector – face a higher probability of initial refusal or restriction of the approved specification to narrower sub-classes of goods.

For foreign law firms advising clients with regional portfolios spanning Russia, Kazakhstan, and other EAEU jurisdictions, the increased divergence between EAEU-level trademark examination practice and Kazpatent's national examination procedure creates a coordination challenge. The EAEU regional trademark route – administered by the Eurasian Patent Organisation (EAPO) – covers member states including Kazakhstan but does not replace the national register for all enforcement purposes. Counsel advising on regional pharmaceutical trademark strategy must now track two distinct examination frameworks simultaneously.

[CTA: If your company holds or is building a pharmaceutical trademark portfolio with exposure to Kazakhstan and the EAEU, make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

Three action areas are most relevant for foreign pharmaceutical companies reviewing their Kazakhstan IP position in light of recent developments.

Conduct a targeted Kazakhstan portfolio audit. The starting point is a mark-by-mark review of existing registrations against the current Kazpatent classification of goods, with particular attention to Class 5 specifications. Broad specifications filed several years ago may no longer reflect the products actually marketed in Kazakhstan or may be vulnerable to non-use cancellation in light of evolving examination standards. For marks not yet registered in Kazakhstan, a filing priority analysis should assess which marks carry the greatest commercial risk if a bad-faith applicant or generic competitor files first – a risk that is heightened in the pharmaceutical sector given the value of brand recognition at the prescriber and pharmacy level.

Align trademark registration with the market authorisation timeline. Given the tighter procedural linkage between trademark status and the pharmaceutical market authorisation pathway, companies should treat trademark registration as an early-stage regulatory task rather than a post-launch compliance step. The practical implication is that the trademark filing should precede or run in parallel with the market authorisation application, not follow it.

Register with Kazpatent Customs and review border measure procedures. The strengthened ex officio powers of Kazakhstan Customs create a practical opportunity. Foreign pharmaceutical trademark holders can register their marks in the customs IP registry to enable border authorities to identify infringing products proactively. This recordal is separate from Kazpatent registration and requires current product descriptions, authorised importer information, and contact details for emergency notifications. For companies that already maintain customs recordals in Russia under the Federal Customs Service registry – a common practice for multinational pharmaceutical brands operating across the Russia–Kazakhstan corridor – a Kazakhstan customs recordal involves separate application requirements and should not be assumed to follow automatically from Russian registration.

For companies with dual exposure across the cross-border Kazakhstan–Russia IP corridor, the practical complexity of maintaining simultaneous national registrations, EAEU regional filings, and customs recordals in both jurisdictions underscores the value of coordinated regional counsel. The IP Protection & Enforcement practice area (/jurisdictions/kazakhstan/ip/) and the broader Kazakhstan practice page (/jurisdictions/kazakhstan/) set out the firm's current advisory capacity in this area.

For companies also considering the analogous challenge in Uzbekistan, the IP framework for that jurisdiction is available at /jurisdictions/uzbekistan/ip/.

[CTA: For coordinated Kazakhstan and EAEU pharmaceutical trademark advice – including customs recordal, portfolio audit, and market authorisation linkage – make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

• IP Protection & Enforcement – Kazakhstan (/jurisdictions/kazakhstan/ip/)
• Kazakhstan Regulatory & Licensing – Pharmaceuticals (/jurisdictions/kazakhstan/regulatory-licensing/)
• Kazakhstan Distribution & Franchising (/jurisdictions/kazakhstan/distribution-franchising/)
• Uzbekistan IP Protection & Enforcement (/jurisdictions/uzbekistan/ip/)

Q: What specifically changed in Kazakhstan's trademark registration framework for pharmaceutical companies?

A: Kazakhstan has strengthened the linkage between trademark registration and pharmaceutical market authorisation, tightened Kazpatent examination standards for descriptive and INN-adjacent marks in line with EAEU norms, and expanded customs border measure powers to allow ex officio detention of suspected counterfeit pharmaceutical products. Taken together, these developments mean that trademark registration in Kazakhstan is now a more integral part of the pharmaceutical regulatory pathway – and the consequences of deferred or incomplete registration are more directly felt during the market authorisation process. Foreign companies that rely solely on EAEU-level or Russian trademark registrations should not assume those registrations provide equivalent protection in Kazakhstan.

Q: Which foreign pharmaceutical companies are most directly affected by these changes?

A: The changes have the broadest effect on three groups: multinational pharmaceutical companies distributing through Kazakhstani distributors whose trademark portfolios have not been updated to reflect current Kazpatent specifications; generic manufacturers whose marks are built on descriptive or INN-adjacent roots and now face stricter examination; and foreign law firms advising on regional portfolios who must navigate both the EAEU regional trademark route (through EAPO) and Kazakhstan's national Kazpatent register simultaneously. Companies operating across the Russia–Kazakhstan corridor face the additional complexity of maintaining separate customs recordals in both jurisdictions, each with distinct procedural requirements.

Vetrov & Partners is a Russian boutique law firm established in 2009, recognised by Pravo-300 – Russia's principal legal directory – for eight consecutive years, and listed as a trusted adviser by the German Consulate General in Novosibirsk.

The firm's IP Protection & Enforcement practice advises foreign pharmaceutical companies, brand owners, and regional counsel on trademark strategy, registration, and enforcement across Russia and the broader EAEU space, including coordinated matters touching Kazakhstan. With over 1,000 matters handled since inception, the team combines deep procedural knowledge of Russian and EAEU IP frameworks with direct partner involvement on every engagement. For Kazakhstan-specific matters, the firm works with trusted local counsel in Almaty and Astana.

We are a Russian-qualified law firm. For matters governed by Kazakhstani law or requiring local admission in Kazakhstan, we collaborate with trusted counsel in the relevant jurisdiction.

Enquiries: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76 | t.me/vitvetcom

This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.

— Aigerim Serikbayeva Contributing Regional Analyst — Kazakhstan · EAEU Trade, Customs & Market Entry vetrovpartners.com/contributions/